2j1x
From Proteopedia
|
HUMAN P53 CORE DOMAIN MUTANT M133L-V203A-Y220C-N239Y-N268D
Contents |
Overview
The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in approximately 50% of human cancers. We have solved high-resolution crystal structures of several oncogenic mutants to investigate the structural basis of inactivation and provide information for designing drugs that may rescue inactivated mutants. We found a variety of structural consequences upon mutation: (i) the removal of an essential contact with DNA, (ii) creation of large, water-accessible crevices or hydrophobic internal cavities with no other structural changes but with a large loss of thermodynamic stability, (iii) distortion of the DNA-binding surface, and (iv) alterations to surfaces not directly involved in DNA binding but involved in domain-domain interactions on binding as a tetramer. These findings explain differences in functional properties and associated phenotypes (e.g., temperature sensitivity). Some mutants have the potential of being rescued by a generic stabilizing drug. In addition, a mutation-induced crevice is a potential target site for a mutant-selective stabilizing drug.
Disease
Known diseases associated with this structure: Adrenal cortical carcinoma OMIM:[191170], Breast cancer OMIM:[191170], Colorectal cancer OMIM:[191170], Hepatocellular carcinoma OMIM:[191170], Histiocytoma OMIM:[191170], Li-Fraumeni syndrome OMIM:[191170], Multiple malignancy syndrome OMIM:[191170], Nasopharyngeal carcinoma OMIM:[191170], Osteosarcoma OMIM:[191170], Pancreatic cancer OMIM:[191170], Thyroid carcinoma OMIM:[191170]
About this Structure
2J1X is a Single protein structure of sequence from Homo sapiens with as ligand. Known structural/functional Site: . Full crystallographic information is available from OCA.
Reference
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs., Joerger AC, Ang HC, Fersht AR, Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15056-61. Epub 2006 Oct 2. PMID:17015838
Page seeded by OCA on Thu Feb 21 17:58:33 2008
Categories: Homo sapiens | Single protein | Fersht, A R. | Joerger, A C. | ZN | Acetylation | Activator | Alternative splicing | Anti-oncogene | Apoptosis | Cell cycle | Disease mutation | Dna-binding | Dna-binding protein | Glycoprotein | Host-virus interaction | Li-fraumeni syndrome | Metal-binding | Nuclear protein | P53 dna-binding domain | Phosphorylation | Polymorphism | Second-site suppressor mutation | Superstable mutant | Transcription | Transcription regulation | Transferase | Tumor suppressor | Zinc
